Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-09-06), PT Soho Global Health Tbk's Beta is 1.0097.
PT Soho Global Health Tbk (ISX:SOHO) Beta Explanation
Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.
Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, PT Soho Global Health Tbk's Beta, along with its competitors' market caps and Beta data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Soho Global Health Tbk Beta vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, PT Soho Global Health Tbk's Beta distribution charts can be found below:
* The bar in red indicates where PT Soho Global Health Tbk's Beta falls into.
Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.
PT Soho Global Health Tbk (ISX:SOHO) has a Beta of 1.0097 as of Sep. 06, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for PT Soho Global Health Tbk and its competitors.
Is PT Soho Global Health Tbk's Beta too high?
PT Soho Global Health Tbk's current Beta is 1.0097. Overall, PT Soho Global Health Tbk has a GF Score™ of 87/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does PT Soho Global Health Tbk's Beta compare to MCK and COR?
PT Soho Global Health Tbk's Beta of 1.0097 can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Medical Distribution company?
A good Beta depends on the Medical Distribution industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for PT Soho Global Health Tbk and its competitors. PT Soho Global Health Tbk's current Beta is 1.0097. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Soho Global Health Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Soho Global Health Tbk (ISX:SOHO) is currently considered Significantly Overvalued. The stock's GF Value™ is Rp805.04, compared to a current price of Rp1,205.00 — trading 49.7% above its estimated fair value. The current Beta is 1.0097. PT Soho Global Health Tbk's overall GF Score™ is 87/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For PT Soho Global Health Tbk (ISX:SOHO), the current Beta is 1.0097 as of Sep. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Soho Global Health Tbk (ISX:SOHO) Overvalued in 2026?
Based on GuruFocus' analysis, PT Soho Global Health Tbk stock appears to be overvalued.
The current stock price of Rp1,205.00 is trading 49.7% above its estimated GF Value™ of Rp805.04.
GuruFocus considers PT Soho Global Health Tbk to be Significantly Overvalued.
Key valuation signals for ISX:SOHO:
Beta: 1.0097
GF Value™: Rp805.04 vs. price of Rp1,205.00 (49.7% above fair value)
No single metric tells the full story. See the ISX:SOHO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Soho Global Health Tbk is a healthcare company operating in the areas of natural/herbal health care products and services. The company manufactures and distributes pharmaceutical products, including herbal cures, proprietary medicines, and health foods, under various brand names such as Curcuma Plus, Curcuma Plus Milk; Imboost; Fitkom; Diapet; Laxing; Lelap; Asthma Soho, and Sohobion. Its segment includes Distribution, Consumer health, Alliance, and others. The company generates maximum revenue from the Distribution segment.
87GF Score
Get the complete analysis for ISX:SOHO
Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:SOHO has been successfully added to your 
